On May 20, 2025, Inovio Pharmaceuticals held its Annual Meeting where stockholders voted on four proposals, including the election of directors and approval of accounting firm Ernst & Young for 2025; 54.59% of shares voted. The proposals results included significant support for board nominees and compensation plans, with the majority favoring the appointments and amendments outlined in the Proxy Statement.